Key Highlights
- Third-quarter Net Income at Terra Innovatum (NASDAQ:NKLR) was USD 61.0 million versus a net loss of USD 3.0 million a year earlier, or USD 0.55 per share.
- A USD 62.2 million unrealized gain on the share-settled contingent Liability and USD 5.3 million on warrants drove the result, not operations.
- Loss from operations rose 210% to USD 7.1 million, as general and administrative costs reached USD 5.4 million and development costs USD 1.7 million.
- Cash was USD 82.4 million on September 30, 2026, which management expects to fund operations for at least 12 months; no Revenue is expected before 2028.
Contingent Liability Revaluation Creates a USD 61.0 Million Profit
Terra Innovatum (NASDAQ:NKLR) filed its Quarterly Report on November 16, 2026. Net income was USD 61.0 million compared with a USD 3.0 million loss in the prior-year quarter. The company is a development-stage nuclear energy technology Business working on SOLO, a micro-modular reactor, and has generated no revenue. The swing came from a USD 62.2 million unrealized gain on the share-settled contingent liability, which covers convertible preferred and sponsor shares that vest on market and regulatory milestones. The filing says the gain mainly reflects a lower share price at quarter-end than three months earlier. Warrant revaluation added USD 5.3 million. These are non-cash accounting entries, so they add nothing to the cash balance. The nine-month figures show the same pattern, with a USD 46.4 million gain on the contingent liability, which followed a USD 15.8 million Fair Value loss on it in the first half (calculated).
Operating Loss Widens 210% as Public Company and NRC Costs Build
Loss from operations was USD 7.1 million versus USD 2.3 million. General and administrative expense rose 155% to USD 5.4 million, including USD 2.5 million of professional, legal and advisory fees, USD 0.7 million of director compensation and USD 0.7 million of insurance. Development costs climbed from USD 0.2 million to USD 1.7 million, with USD 1.2 million for engineering studies and consultants and USD 0.3 million of Nuclear Regulatory Commission pre-application fees. About USD 0.8 million of costs from the new U.S. Subsidiary for April through June were booked in the third quarter. Over nine months net income was USD 35.9 million against a USD 5.6 million loss, while the operating loss was USD 19.8 million. Management expects administrative costs to keep rising in absolute dollars as a public company, with higher insurance, listing and compliance spending, and a larger U.S. team.
USD 82.4 Million Cash Balance Against a USD 134.8 Million Contingent Liability
Cash and cash equivalents were USD 82.4 million versus USD 102.9 million at year-end 2025, and operating cash outflow was USD 19.6 million for nine months. Total liabilities were USD 146.8 million, mostly the USD 134.8 million share-settled contingent liability, leaving a shareholders Deficit of USD 55.1 million. Management assigns roughly 89% and 80% probabilities to the remaining regulatory milestones, expected between mid-2027 and early 2028. It does not expect meaningful revenue before 2028 and says more Capital will be needed to finish development and licensing. Because the liability is tied to the share price, it can swing Earnings in either direction.
Where Things Stand
The profit is a bookkeeping result, not a business turnaround. Terra Innovatum (NASDAQ:NKLR) has no revenue, an operating loss of USD 7.1 million for the quarter and USD 82.4 million of cash. The USD 61.0 million of net income reflects a lower value placed on contingent share obligations and warrants. Next markers are regulatory milestones for SOLO expected in 2027 and 2028, quarterly cash burn, any new financing and how the liability moves with the share price.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...